Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 03 2019
06 03 2019
Historique:
received:
07
08
2018
accepted:
06
02
2019
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
2
10
2020
Statut:
epublish
Résumé
Factor V serves an important role in the regulation of blood coagulation. The rs6025 (R534Q) and rs4524 (K858R) polymorphisms in the F5 gene, are known to influence the risk of venous thrombosis. While the rare Q534 (factor V Leiden) allele is associated with an increased risk of venous thrombosis, the minor R858 allele is associated with a lower risk of disease. However, no study has deeply examined the cumulative impact of these two variations on venous thrombosis risk. We study the association of these polymorphisms with the risk of venous thrombosis in 4 French case-control populations comprising 3719 patients and 4086 controls. We demonstrate that the Q534 allele has a dominant effect over R858. Besides, we show that in individuals not carrying the Q534 allele, the protective effect of the R858 allele acts in a dominant mode. Thrombin generation-based normalized activated protein C sensitivity ratio was lower in the 858R/R homozygotes than in the 858K/K homozygotes (1.92 ± 1.61 vs 2.81 ± 1.57, p = 0.025). We demonstrate that the R858 allele of the F5 rs4524 variant protects from venous thrombosis only in non-carriers of the Q534 allele of the F5 rs6025. Its protective effect is mediated by reduced factor VIII levels and reduced activated protein C resistance.
Identifiants
pubmed: 30842582
doi: 10.1038/s41598-019-40172-x
pii: 10.1038/s41598-019-40172-x
pmc: PMC6403374
doi:
Substances chimiques
Protein C
0
factor V Leiden
0
Factor V
9001-24-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3750Références
Haematologica. 2016 Sep;101(9):1046-53
pubmed: 27479824
J Thromb Haemost. 2005 Dec;3(12):2695-702
pubmed: 16359508
J Biol Chem. 2017 Jun 2;292(22):9335-9344
pubmed: 28420729
PLoS One. 2012;7(6):e38538
pubmed: 22675575
Circ Res. 2005 Nov 11;97(10):1070-6
pubmed: 16210545
J Clin Invest. 2013 Sep;123(9):3777-87
pubmed: 23979162
J Thromb Haemost. 2017 Jan;15(1):140-149
pubmed: 27801970
Thromb Haemost. 1996 Apr;75(4):562-6
pubmed: 8743179
Int J Lab Hematol. 2016 May;38 Suppl 1:4-11
pubmed: 27161771
Br J Haematol. 2012 Jun;157(6):753-61
pubmed: 22533697
Thromb Res. 2000 Sep 15;99(6):539-47
pubmed: 10974338
Thromb Haemost. 2003 Jun;89(6):983-9
pubmed: 12783110
Hum Mol Genet. 2003 Jan 15;12(2):111-23
pubmed: 12499392
Am J Hum Genet. 1988 Jan;42(1):113-24
pubmed: 2892394
JAMA. 2010 Feb 3;303(5):421-2
pubmed: 20124536
Sci Rep. 2017 Apr 04;7:45507
pubmed: 28374852
Nature. 1994 May 5;369(6475):64-7
pubmed: 8164741
JAMA. 2007 Feb 7;297(5):489-98
pubmed: 17284699
Thromb Haemost. 2016 Mar;115(3):580-90
pubmed: 26607136
J Thromb Haemost. 2005 Jul;3(7):1488-94
pubmed: 15978106
Thromb Haemost. 2007 Sep;98(3):530-42
pubmed: 17849041
J Biol Chem. 1994 Jul 22;269(29):18735-8
pubmed: 8034625
Eur J Hum Genet. 2002 Sep;10(9):553-61
pubmed: 12173033
Bioinformatics. 2007 Apr 15;23(8):1038-9
pubmed: 17308338
Br J Haematol. 2012 Apr;157(2):230-9
pubmed: 22443383
Hum Mol Genet. 2002 Aug 15;11(17):2015-23
pubmed: 12165563
J Biol Chem. 1998 Jun 26;273(26):16140-5
pubmed: 9632668
J Thromb Haemost. 2006 Jan;4(1):35-40
pubmed: 16246256
J Thromb Haemost. 2011 Jul;9 Suppl 1:258-64
pubmed: 21781262
Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53
pubmed: 13679651
J Thromb Haemost. 2009 Oct;7(10):1743-6
pubmed: 19682239
Am J Hum Genet. 2015 Apr 2;96(4):532-42
pubmed: 25772935
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17838-43
pubmed: 24127605